John Young is Group President of Pfizer’s Essential Health business, which encompasses both developed and emerging markets and includes the company’s portfolio of established products; patented products that will lose exclusivity in the near term; partnerships with Mylan, Hisun and Teuto; and Biosimilars.
John joined Pfizer in 1987 as a Sales Representative in his native Scotland and is an experienced biopharmaceutical leader who has served Pfizer in a variety of sales, marketing, and executive management roles. Prior to assuming leadership of the Global Established Pharma business, John led Pfizer’s global Primary Care organization. Earlier in his career, he served in the role of Regional President for PECANZ (Primary Care Europe, Canada, Australia, New Zealand), and before that was country manager in the UK (2007-2009) and Australia (2004-2007).
John’s long and successful career with Pfizer has been marked by forging agreements with governments to provide patient access to innovative medicines, and a commitment to talent development and culture. He is currently a board member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), as well as the National Committee for US-China Relations (NCUSCR). During his time in Australia, John served as Chair of the local industry association, Medicines Australia, and led successful industry negotiations with that government on Pharmaceutical Benefits Scheme (PBS) reform. Building on this experience, in the UK, John was among the industry leaders responsible for re-negotiating the Pharmaceutical Price Regulation Scheme (PPRS). To help support a diverse workplace, John is the executive sponsor of the Asian Pfizer Colleague Council. He is also active in community work to serve vulnerable populations.
John holds a Bachelor of Science degree in Biology from Glasgow University and an MBA from Strathclyde Graduate Business School.